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Induction of NF-κB by the Akt/PKB kinase
Lawrence P. Kane*, Virginia Smith Shapiro*, David Stokoe† and Arthur Weiss*‡
The serine/threonine kinase Akt (also known as protein
kinase B, PKB) is activated by numerous growth-factor
and immune receptors through lipid products of
phosphatidylinositol (PI) 3-kinase. Akt can couple to
pathways that regulate glucose metabolism or cell
survival [1]. Akt can also regulate several transcription
factors, including E2F, CREB, and the Forkhead family
member Daf-16 [2–4]. Here, we show that Akt can
regulate signaling pathways that lead to induction of the
NF-κB family of transcription factors in the Jurkat T-cell
line. This induction occurs, at least in part, at the level of
degradation of the NF-κBinhibitor IκB, and is specific for
NF-κB, as other inducible transcription factors are not
affected by Akt overexpression. Furthermore, the effect
requires the kinase activity and pleckstrin homology
(PH) domain of Akt. Also, Akt does not act alone to
induce cytokine promoters and NF-κB reporters,
because signals from other pathways are required to
observe the effect. These studies uncover a previously
unappreciated connection between Akt and NF-κB
induction that could have implications for the control of
T-cell growth and survival.
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Results and discussion
The promoter of the interleukin-2 (IL-2) gene has pro-
vided a model system with which to study signals down-
stream of the T-cell receptor (TCR) and the CD28
co-stimulatory receptor [5–7]. To investigate the potential
role of Akt in T-cell activation, Jurkat T cells were co-
transfected with an expression vector encoding Akt and a
reporter plasmid containing the luciferase gene driven by
the IL-2 promoter. Overexpression of Akt in Jurkat cells
led to a 7–10-fold increase in IL-2 promoter activity over
that obtained by stimulation with phorbol myristate
acetate (PMA) and ionomycin alone (Figure 1a). Intrigu-
ingly, the effect is similar to that seen when CD28 (but
not the TCR) is crosslinked in conjunction with the sub-
maximal stimulus of PMA and ionomycin (data not shown;
[6]). Overexpression of Akt had no effect on the basal
level of IL-2 promoter activity (data not shown).
The IL-2 promoter contains a number of binding sites for
transcription factors, including sites for NFAT, AP-1,
NF-κB, and a CD28-responsive element/AP-1 composite
site (termed RE/AP) [6,8]. Reporter plasmids containing
individual binding sites from the IL-2 promoter were
assayed using soluble anti-TCR antibody and PMA as
stimuli, as they provide an efficient but sub-maximal stim-
ulus. Little if any effect of Akt overexpression was seen on
luciferase reporter plasmids driven by AP-1- or NFAT-
binding sites (Figure 1a), but when a reporter driven by
the NF-κB consensus site from the human immunodefi-
ciency virus long terminal repeat (HIV LTR) or the
RE/AP-binding site from the IL-2 promoter was exam-
ined, a dramatic potentiation was noted upon Akt overex-
pression. As with the IL-2 promoter, Akt overexpression
did not affect the basal level of transcription from any of
these individual elements (data not shown). Akt was
expressed at comparable levels in all transfections
(Figure 1a, inset). The selective enhancement by Akt of
NF-κB and RE/AP reporters suggested that Akt was
specifically influencing NF-κB induction. The conse-
quences of Akt overexpression for other NF-κB-depen-
dent reporter plasmids were investigated. Only certain
responses of reporters driven by NF-κB elements from
the major histocompatibility complex (MHC) class I pro-
moter (Figure 1b), the RE/AP site (see above) or the IL-2
receptor α chain promoter (data not shown) were strongly
augmented by Akt. The effect of Akt was most striking in
conjunction with a low concentration of PMA. 
The NF-κB reporter assays were repeated with various
mutants of Akt. An inactivating mutation of the kinase
domain or deletion of the PH domain prevented Akt from
potentiating NF-κB-dependent transcription (Figure 2a).
A myristylated version of Akt, which is targeted to the
plasma membrane and is constitutively active, was also
capable of increasing transcription from NF-κB-binding
sites. Thus, Akt augmentation of NF-κB activity requires
Akt kinase activity and the Akt PH domain.
As Akt is activated in part by products of PI 3-kinase, we
determined whether the effect of Akt on NF-κB induc-
tion was dependent upon cellular PI 3-kinase activity,
using the PI 3-kinase inhibitors LY294002 and wortman-
nin [9,10]. Both LY294002 (Figure 2b) and wortmannin
(data not shown) could effectively inhibit the potentiation
of RE/AP reporter (or NF-κB reporter; data not shown)
activity by wild-type Akt in the presence of PMA, demon-
strating that endogenous PI 3-kinase activity is required.
The inhibitors did not block induction of reporter activity
by PMA and myristylated Akt (Figure 2b and data not
shown), however, consistent with reports that membrane-
targeted Akt is partially PI 3-kinase independent
[1,11,12]. An activated, membrane-targeted form of PI
3-kinase, p110–CAAX [13], potentiated the induction of
NF-κB activity by Akt and PMA (Figure 2c), but did not
affect RE/AP or NF-κB activity in the absence of Akt
expression, with or without PMA (Figure 2c and data not
shown). Thus, although PI 3-kinase activity is required for
NF-κB induction by Akt, PI 3-kinase overexpression
alone is not capable of mediating such an effect. However,
other potential targets of p110 include proteins such as
Itk, Vav, and phospholipase Cγ [14–16].
We examined whether stimulation of Jurkat cells with PMA
and Akt resulted in increased nuclear levels of NF-κB pro-
teins that could bind to NF-κB-binding sites. These experi-
ments were conducted with Jurkat cell lines stably
expressing myristylated Akt, which mediates stronger
NF-κB-mediated transcriptional activation than wild-type
Akt in stable cell lines (data not shown). Low levels of
nuclear NF-κB-binding factors were seen when a control
clone was stimulated with PMA alone, with significantly
higher levels when anti-CD28 antibody was also added as a
positive control. By contrast, clones expressing myristylated
Akt yielded significantly higher nuclear levels of NF-κB-
binding complexes. These results suggest that the strong
transcriptional upregulation by Akt is due, at least in part, to
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Figure 1
Effect of Akt overexpression on inducible
transcription in T cells. Jurkat cells were
transfected by electroporation and stimulated
18 h later for 6 h (see Supplementary material
published with this paper on the internet).
Reporter plasmid (20 µg) was co-transfected
with 10 µg empty vector (Vector) or vector
containing Akt. PMA was used at 10 ng/ml,
ionomycin (iono) at 1 µM, and soluble anti-
TCR antibodies (C305 culture supernatant) at
a 1:1,000 dilution. Data shown are the average
of three experiments ± standard deviation
(SD). (a) Reporter plasmids containing
luciferase driven by the individual transcription
factor binding sites (NFAT, AP-1, NF-κB and
RE/AP) or the full-length IL-2 promoter (IL-2)
were assayed. The inset in (a) shows samples
of a representative transfection (106 cell
equivalents) analyzed for Akt expression
(upper band) by western blotting. (b) Reporter
plasmids containing luciferase driven by the
NF-κB-binding site from the MHC class I
promoter or by the IL-2 RE/AP site, as
indicated, were assayed. The fold stimulation
refers to the fold stimulation over that obtained
in the absence of any stimulation. 
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The kinase and PH domains of Akt are required to augment NF-κB
induction in conjunction with PI 3-kinase activity. Jurkat cells were
transfected and stimulated as described in Figure 1. (a) Cells were
transfected with 20 µg reporter driven by the NF-κB-binding site from
the HIV LTR and 10 µg of the indicated Akt expression plasmids: WT,
wild type; KD, kinase-deficient; ∆PH, PH domain deleted; Myr,
myristylated. Vector represents the empty vector control. (b,c) Cells
were transfected with 20 µg RE/AP-driven reporter and 10 µg (except
where otherwise noted) of the indicated Akt or p110 expression
plasmids. PMA was added at 10 ng/ml in all cases and LY294002
was added at 20 µM. Data presented are representative of three to five
independent experiments.
increased NF-κB levels in the nucleus, which would be
expected to result from degradation of IκB proteins. 
The requirement for IκB degradation in NF-κB activation
by Akt was first addressed with a mutant form of IκB-α
(IκB-AA) that contains serine-to-alanine mutations of the
sites required for phosphorylation and degradation.
IκB-AA therefore cannot be phosphorylated and degraded
and acts as a potent inhibitor of NF-κB activation [17].
IκB-AA potently inhibited the activation of a NF-κB-
driven reporter by various stimuli, including PMA and Akt
(Figure 3b). IκB-AA also inhibited activation of the
RE/AP-driven reporter, but not of an NFAT-driven
reporter (data not shown). Similar results were seen with
MG-132, a proteasome inhibitor which prevents IκB
degradation [17] (data not shown). These experiments
implicate the involvement of IκB in Akt-mediated NF-κB
induction. To examine this more directly, tagged forms of
IκB-α and IκB-β were expressed in Jurkat cells, with or
without Akt overexpression. The degradation of IκB was
then followed, after treatment with PMA and cyclohex-
imide, which was added to prevent NF-κB-mediated IκB
re-expression. PMA treatment alone was sufficient to
effect moderate to complete degradation of IκB-α, but
this occurred more efficiently in cells overexpressing Akt
(Figure 3c). The effect on IκB-β was even more dramatic,
in that PMA did not induce significant degradation of
IκB-β unless cells overexpressed Akt.
We tested whether known IκB kinases [18] were required
for Akt-mediated NF-κB activation. The IκB kinases
IKK-α and IKK-β directly phosphorylate IκB-α and IκB-β
on the two serine residues that are critical for IκB ubiquiti-
nation and degradation. Kinase-deficient IKK-α or IKK-β
was co-transfected with Akt. These kinase-deficient forms
of IKK-α or IKK-β inhibited the activation of an NF-κB-
driven reporter by PMA and Akt, but did not affect Akt
expression (Figure 4a) or transfection efficiency (data not
shown). NF-κB-inducing kinase (NIK) has also been
implicated in NF-κB activation (reviewed in [18]). A
kinase-deficient form of NIK [19] was transfected into
Jurkat cells with Akt and specific inhibition of NF-κB
reporter activity was also observed in these cells after
stimulation with PMA (Figure 4a), without a significant
effect on expression of Akt or transfection efficiency (data
not shown). Finally, the effect of Akt on IKK activation
was assessed directly. Empty vector or an Akt expression
vector was co-transfected with a vector encoding epitope-
tagged IKK-α. As shown in Figure 4b, PMA alone (at
10 ng/ml) was unable to activate IKK-α in cells trans-
fected with empty vector, but could activate IKK-α when
Akt was overexpressed. 
The results presented here are consistent with a model
whereby Akt and other signals act upstream of the IKKs in
effecting NF-κB induction. Akt may contribute to NF-κB
induction by a subset of receptors in T cells, such as the
TCR, CD28, or the IL-1 receptor [20]. We are currently
investigating whether these or other receptors require Akt
activation in order to mediate inducible transcription. We
are also interested in identifying the direct target(s) for
Akt in the NF-κB pathway. The IKKs, IκBs and NIK do
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Induction of NF-κB DNA-binding activity and IκB degradation by Akt.
(a) Jurkat cells expressing myristylated Akt (1A11 and 1D10) or cells
carrying a control, empty vector were treated with the indicated stimuli
for 4 h. Nuclear extracts were prepared and gel shift assays carried out
(see Supplementary material). Complex I contains p50–p50
homodimers and complex II contains p50–p65 and p50–c-Rel
heterodimers. (b) Jurkat cells were transfected with 20 µg HIV NF-κB-
driven reporter and the indicated plasmids carrying Akt or IκB-AA
(10 µg or 2 µg, respectively). Cells were stimulated as described in
Figure 1. Anti-CD28 ascites was used at 1:10,000 dilution. (c) Jurkat
cells were transfected with 10 µg each of FLAG-tagged IκB-α and
IκB-β and 10 µg empty pCDEF3 vector (vector) or 10 µg pCDEF3
carrying EE-tagged wild-type Akt (Akt). Cells were pretreated with
50 µg/ml cycloheximide for 15 min, then stimulated with 10 ng/ml PMA
for the indicated times. Whole-cell lysates were analyzed by western
blotting for expression of IκB-α, IκB-β, and Akt. Results are
representative of three independent experiments. 
not contain a consensus sequence for phosphorylation by
Akt, as defined by Alessi et al. [21]. Akt may therefore lead
to IKK activation through a MAPKKK family member
other than NIK or, alternatively, Akt may target a previ-
ously unknown pathway for IKK activation.
Supplementary material
Additional methodological detail is published with this paper on the
internet.
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Figure 4
Activation of NF-κB by Akt requires the IκB
kinases and NIK. (a) Jurkat cells were
transfected with 20 µg HIV NF-κB-driven
reporter and empty pCDNA3 vector (V) or
increasing amounts of the indicated kinase-
deficient (KD) kinases, along with 10 µg wild-
type Akt. Kinase-deficient IKKs were
transfected at 2, 8 and 20 µg, whereas
kinase-deficient NIK was transfected at 1, 5
and 10 µg. Cells were stimulated with
10 ng/ml PMA. The insets show
representative examples of levels of Akt
expression for each of the experiments, as
analyzed by western blotting. (b) Jurkat cells
were co-transfected with FLAG-tagged IKK-α
and either empty vector or Akt. The next day,
cells were either stimulated with PMA alone
(10 ng/ml) or left untreated, and IKK activity
(upper panels) was determined (see
Supplementary material). The protein levels
of transfected IKK-α are also shown (lower
panels). Results are representative of three
independent experiments.
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Supplementary materials and methods
Plasmids
The IL-2 promoter reporter contains 275 bp upstream of the IL-2 tran-
scriptional start site [S1]. NF-κB reporters were from the following
sources: HIV, from Jorge Moscat and MHC class I from Albert Baldwin.
The IL-2 receptor α NF-κB and IL-2 RE/AP reporters were described
previously [S2,S3]. NFAT and AP-1 luciferase reporters have been
described previously [S2]. The pCMV4 vectors encoding FLAG-
tagged IκB-α and IκB-β were from Dean Ballard; kinase-deficient NIK,
and IKKs were from Warner Greene; p110–CAAX was from Julian
Downward; FLAG–IKK-α was from David Goeddel.
Antibodies and biochemicals
Polyclonal antibodies directed against Akt (C-20) and IκB-β (C-20)
were obtained from Santa Cruz Biotechnology. Antiserum specific for
IκB-α was from Joseph Didonato. Murine IgM (clone C305) specific for
the Jurkat TCR was produced in a Miniperm apparatus and used at a
dilution of 1:1,000. Anti-human CD28 ascites (clone 9.3) was obtained
from Bristol-Myers Squibb, and used at a 1:2,000 dilution. Anti-FLAG
antibody M2 was obtained from Sigma Chemical Co. PMA, cyclohex-
imide, LY294002, and wortmannin were obtained from Calbiochem. 
Transfections and luciferase assays
Jurkat cells were transfected by electroporation. Cells grown to a
density of 0.5–1.0 × 106 per ml were washed into room-temperature,
serum-free RPMI at a final density of 3 × 107/ml. Cells (0.4 ml) were
added to a 0.4 cm gap cuvette (Invitrogen) containing plasmid DNA, as
indicated. Electroporation was carried out at 250 V, 960 µF. Cells were
immediately transferred to a small tissue culture plate with 10 ml RPMI
containing 5% FCS and cultured for 16–18 h at 37°C, 5% CO2. For
generation of stable cell lines, cells were plated at various dilutions in
96-well plates, in complete medium containing 2 mg/ml G418. Several
weeks later, clones were transferred and expanded. Expression of
tagged Akt was confirmed with a polyclonal antiserum specific for Akt. 
For luciferase assays, the cells were washed and resuspended at
2 × 106 per ml in RPMI containing 5% FCS. Cells were aliquotted into
round-bottom 96-well plates (50 µl) with RPMI+FCS containing 2×
concentration of the indicated stimuli (50 µl). After 6 h at 37°C, 5%
CO2, cells were permeabilized with 11 ml luciferase harvest buffer
(10% Triton X-100, 1 mM DTT, 0.2 M KPO4 pH 7.8). After 5 min at
room temperature, samples were transferred to an opaque 96-well
plate, and 100 µl of luciferase assay buffer was added (10 mM ATP,
20 mM MgCl2, 0.2 M KPO4 pH 7.8). Luciferase activity was deter-
mined in a MicroLumat luminometer (EG&G Berthold), with a 10 sec
reading, after injection of 50 µl 1 mM luciferin.
Gel shift assays
Before preparation of nuclear extracts, Jurkat cells were treated for 4 h
in RPMI+FCS, as indicated. Cells (107) were pelleted and washed
twice with PBS. The final pellet was resuspended in 0.8 ml buffer A
(10 mM HEPES-KOH pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 1 mM DTT, 0.5 mM PMSF) and left on ice for 15 min. NP-40
was added to 0.5% and samples vortexed for 20 sec, then spun for
30 sec at maximum speed. The supernatant was discarded and the
pellet washed with 0.5 ml buffer A. The pellet was solubilized with
0.1 ml buffer C (20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA,
1 mM EGTA, 1 mM DTT, 0.5 mM PMSF) by gently agitating for 20 min.
Samples were spun for 10 min at maximum speed in a microfuge and
the supernatants saved and quantitated for protein levels.
Nuclear extracts (6 µg) were mixed with buffer, 32P-labeled NF-κB
probe [S3], and poly(dI-dC) in a final volume of 20 µl. Reactions were
incubated for 20 min at room temperature. Half of each reaction was
loaded on a 4% acrylamide–TBE gel. Gels were dried and exposed to
X-OMAT film for 8–24 h.
SDS–PAGE and western blotting
Whole-cell lysates were prepared by lysing 106 cells in lysis buffer (1%
NP-40, 150 mM NaCl, 20 mM Tris pH 7.5 + protease inhibitors) at
4 × 107 cells/ml. After incubation on ice for 10 min, lysates were spun
for 10 min at maximum speed in a microcentrifuge. Post-nuclear super-
natants were mixed with 4× reducing sample buffer and boiled for
5 min. Samples were separated on a 10% polyacrylamide gel, which
was then transferred to PVDF membrane (Millipore) using a semi-dry
blotting apparatus. Blots were blocked with 5% non-fat milk in wash
buffer (250 mM NaCl, 20 mM Tris pH 7.5, 0.05% Tween-20) for 2 h at
room temperature. Primary antibody was incubated for 1 h at room tem-
perature in wash buffer, followed by three 10 min washes. Horseradish-
peroxidase-conjugated secondary antibody was diluted to 1:10,000 in
wash buffer and incubated with blots for 1 h at room temperature, fol-
lowed by three 15 min washes, and development by enhanced chemi-
luminescence (Amersham).
IKK kinase assays
Jurkat T cells were transfected, as above, with FLAG-tagged IKK and
indicated additional plasmids. Cells were harvested 20 h later and
washed with PBS. A total of 107 cells per condition were resuspended
in RPMI and stimulated for 20 min at 37°C. Cells were washed once in
ice-cold PBS and lysed in 800 µl lysis buffer (1% NP-40, 250 mM
NaCl, 1 mM EDTA, 50 mM Hepes pH 7.4) + protease inhibitors. IKK
was immunoprecipitated from post-nuclear supernatants with M2 anti-
body coupled to protein-G beads, with rotation for 2 h. Beads were
washed three times with lysis buffer and once with kinase buffer (1 mM
MnCl2, 5 mM MgCl2, 10 mM HEPES pH 7.4) + phosphatase inhibitors.
Reactions were carried out for 30 min at 30°C in 20 µl kinase buffer
with 1 µg GST–IκB and 5 µCi [γ-32P]ATP. Reactions were stopped by
the addition of SDS sample buffer. Samples were boiled for 5 min, sep-
arated by SDS–PAGE and blotted to PVDF. Blots were exposed to film
overnight to determine kinase activity, then blocked and probed for IKK
levels with a polyclonal IKK antibody.
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